skip to primary navigationskip to content

Spinout company Stroma Biosciences selected to take place in Accelerate@Babraham Start-up Programme

last modified Sep 23, 2020 01:43 PM
Spinout company Stroma Biosciences, co-founded by Cambridge Stem Cell Institute and Department of Haematology PI Dr Ingo Ringshausen and post-doc Dr Eugene Park has been selected as one of four start-up companies taking part in the Accelerate@Babraham Start-up Programme.

As part of the Accelerate@Babraham Programme, Stroma Biosciences have secured five months access to Accelerate@Babraham’s bio-incubator facilities, including use of communal equipped laboratory space and flexible workspaces. The company also receives £10,000 of funding, personal mentoring and access to the Babraham Research Campus’ networks.

Stroma Biosciences is a spinout company based on research from the Ringshausen lab looking at the tumour microenvironment and the development of therapeutics targeting stroma-intrinsic mechanisms responsible for environment-mediated drug resistance (EMDR) and immune modulation in cancer and autoimmune disorders.

Co-founder Dr Eugene Park said: “We are honoured to be selected for the 2020 cohort of Accelerate@Babraham. Attracted by its world-class advisory network, we view Accelerate@Babraham as one of the most meaningful paths to begin the translation of our Cancer Research UK funded research of the tumour micro-environment into pre-clinical therapies. We see Accelerate@Babraham as a pre-eminent platform within the entrepreneurial ecosystem that enables early stage ventures to define and implement their core business case, and we value this extraordinary opportunity to further develop Stroma Biosciences.”

Find out more about the Accelerate@Babraham programme here and follow Stroma Biosciences on Twitter for their latest updates.